MannKind (FRA:NNFN) Short-Term Debt : €18.4 Mil (As of Mar. 2024)

View and export this data going back to . Start your Free Trial

What is MannKind Short-Term Debt?

MannKind's Short-Term Debt for the quarter that ended in Mar. 2024 was €18.4 Mil.

MannKind's quarterly Short-Term Debt declined from Sep. 2023 (€18.7 Mil) to Dec. 2023 (€18.3 Mil) but then increased from Dec. 2023 (€18.3 Mil) to Mar. 2024 (€18.4 Mil).

MannKind's annual Short-Term Debt increased from Dec. 2021 (€6.2 Mil) to Dec. 2022 (€9.0 Mil) and increased from Dec. 2022 (€9.0 Mil) to Dec. 2023 (€18.3 Mil).

MannKind Short-Term Debt Historical Data

The historical data trend for MannKind's Short-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

MannKind Short-Term Debt Chart

MannKind Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Short-Term Debt

Get a 7-Day Free Trial

4.53

3.34

6.18

9.03

18.34

MannKind Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Short-Term Debt	Get a 7-Day Free Trial															10.90	15.38	18.74	18.34	18.40

MannKind Short-Term Debt Explanation

Short-Term Debt represents the total amount of Long-Term Debt such as bank loans and commercial paper, which is due within one year.

MannKind Short-Term Debt Related Terms

Thank you for viewing the detailed overview of MannKind's Short-Term Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

MannKind (FRA:NNFN) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » MannKind Corp (FRA:NNFN) » Definitions » Short-Term Debt

Comparable Companies

Traded in Other Exchanges

MNKD:USA

Address

1 Casper Street, Danbury, CT, USA, 06810

Website

https://www.mannkindcorp.com

MannKind Corp is a biopharmaceutical company focused on the development and commercialization of inhaled therapeutic products for patients with diseases such as diabetes and pulmonary arterial hypertension. Its approved product, Afrezza (insulin human) Inhalation Powder, is an ultra-rapid-acting inhaled insulin used to improve glycemic control in adults with diabetes. The product consists of a dry powder formulation of human insulin delivered from a small portable inhaler.

MannKind (FRA:NNFN) Headlines

No Headlines